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Abstract
Background: Continuing the administration of magnesium sulphate for 24 hours after the last fit
in patients with eclampsia is at best empirical. The challenge of such a regimen is enormous in low-
resource countries. The objective of this study was to assess the effectiveness of an ultra-short
regimen of magnesium sulphate in eclamptics.
Findings: This was a prospective, cohort study of eclamptic patients admitted between July 2007
and June 2008 that were given 4 grams magnesium sulphate intravenously and 10 grams
intramuscularly (5 grams in each buttock) as the sole anticonvulsant agent. Main outcome measure
was the absence of a repeat fit. Other aspects of eclampsia management were as in standard
practice. One hundred and twenty one (121) patients were managed with this regimen. There were
29 ante partum, 76 intrapartum and 16 post partum cases of eclampsia. Most of the patients were
primigravidae (100; 83%) with an average age of 18.7 years. There were nine cases (7.4%) of
recurrent fits that occurred within four hours of the loading dose. One recurrent fit occurred in
the ante partum group, seven in the intra partum and one in the post partum group. There were
12 maternal deaths giving a case fatality rate of 9.9%.
Conclusion: Limiting the dosage of magnesium sulphate to 14 grams loading dose (4 grams
intravenous and 10 grams intramuscular) was effective in controlling fits in 92.6% of cases in the
study group. A properly conducted, randomized controlled trial is needed to test our proposed
regimen.
Background
Pre-eclampsia and eclampsia account for about 9% of
maternal deaths in Africa and Asia and about one-quarter
of maternal deaths in Latin America and the Caribbean
[1]. In some parts of northern Nigeria, eclampsia alone
contributes to almost one third of maternal mortality [2-
4]. It is has been established that magnesium sulphate is
the anticonvulsant of choice for both prevention and
treatment of eclampsia [5,6]. But the routine 24-hour
administration of maintenance doses of magnesium sul-
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phate after a loading dose to all patients with eclampsia
[7,8] has not been properly subjected to scientific scru-
tiny.
The exact mechanism of action of magnesium sulphate is
also not clearly understood. Some workers have suggested
the blockade of N-methyl D-aspartate (NMDA) receptors
involved in seizure genesis [9] or calcium channel block-
ing, preventing cerebral vasospasm [10]. The concept of
'one-size-fits-all' in magnesium sulphate administration is
also as curious as it is interesting.
A potential concern for magnesium sulphate therapy is
the risk of side effects which could increase with the dura-
tion of treatment especially if there are challenges in clin-
ical monitoring of the patients. Similarly, the cost of
therapy would inevitably increase with the duration of
treatment. For example with the standard Pritchard regi-
men [8] in which 5 grams of magnesium sulphate is
administered four-hourly for 24 hours after loading with
14 grams; a patient would require at least 44 grams of the
drug to complete a course. And at the retail pharmacy
where 10 mls ampoule of 50% magnesium sulphate cost
one hundred and fifty naira (about a dollar), a patient
would require one thousand two hundred naira (about
nine dollars) for a course of the drug. Meanwhile, only
one-third of the drug (14 grams) and the amount (about
three dollars) would have been required if the regimen
was limited to just the loading dose. Although the drug is
portrayed as cheap in most western literature and the
developed countries, it is neither cheap nor easily availa-
ble in many developing countries [11]. Therefore any
effective regimen that would require less medication and
labor would be attractive to health care providers espe-
cially in resource-poor countries. Begum and co-workers
[12] had earlier reported the effectiveness of a low dose
regimen for eclamptics in which the loading dose was
reduced from the usual 14 grams to 10 grams and 2.5
grams (instead of the traditional 5 grams) was adminis-
tered four-hourly for 24 hours as maintenance doses.
Ekele and Ahmed [13] previously reported success with a
12-hour maintenance regimen instead of the traditional
24 hours and there was a recent report from India with
smaller doses [14]. The question still being asked is
whether the loading dose alone would suffice [15]? Inci-
dentally most of the quest for smaller, shorter or simpler
but effective and safe regimen seems to be coming from
researchers in developing countries probably because of
the peculiar challenges and constraints in those settings.
The objective of this study was to determine the effective-
ness of an ultra short regimen of magnesium sulphate in
the control of fits in patients with eclampsia.
Methods
This was a prospective, cohort study of patients with
eclampsia managed from July 2007 to June 2008 at the
Maternity Unit, Specialist Hospital, Sokoto, Nigeria, after
obtaining institutional ethical approval.
Sokoto, where the study was undertaken is the capital city
of Sokoto state in north western Nigeria. Islam is the pre-
dominant religion of the people with the practice of 'pur-
dah'  (women seclusion) and early girl marriage is not
uncommon in the community.
The hospital is a state-owned tertiary health facility
located in the centre of the town. Apart from attending to
referred cases, it has liberal admission policy including
the acceptance of patients that come directly from their
homes for normal delivery and those with complications.
Eclampsia is diagnosed if there was history of generalized
tonic-clonic convulsions, elevated blood pressure and
proteinuria provided there was no previous history of sei-
zure disorders like epilepsy. If there was doubt about the
diagnosis because the accompanying relation(s) did not
witness the seizure and there was no elevated blood pres-
sure at admission, the patient was excluded from the
study. Also excluded from the study were six patients that
had diazepam as anticonvulsant prior to admission. At
admission each patient that fulfilled the inclusion criteria
had 4 gm of magnesium sulphate administered slowly
intravenously over 10 minutes and 5 gm given deep intra-
muscularly in each buttock making a total loading dose of
14 gm. If there was a repeat fit after the loading dose, an
additional 2 gm magnesium sulphate was given intrave-
nously and the maintenance dose of 5 gm intramuscularly
was then continued for 12 hours of delivery or the last fit
depending on which occurred later. Hydralazine injection
was the antihypertensive used to control severe hyperten-
sion and was administered as intermittent bolus doses to
keep diastolic blood pressure at about 90 mmHg. Methyl-
dopa and nifedipine were the long term anti-hypertensive
agents used. Obstetric management was carried out after
stabilizing each patient. Patients with unfavorable cervix
but adequate pelvis had induction of labor after cervical
ripening with Misoprostol. Those admitted in labor with
no contraindication for vaginal delivery were monitored
and allowed vaginal delivery. Cesarean section was indi-
cated for cephalo-pelvic disproportion or fetal distress.
Craniotomy was performed if the patient was already in
obstructed labor on admission with fetal demise. Babies
with birth asphyxia and low birth weights were managed
at the Special Care Baby Unit.
Results
One hundred and twenty one patients (121) were man-
aged using this regimen. There were 2,313 total deliveriesBMC Research Notes 2009, 2:165 http://www.biomedcentral.com/1756-0500/2/165
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within the study period given an incidence of 5.2% of
maternities. Most of the patients (96 cases; 79%) had no
antenatal care. The age range was from 14 years to 38 years
with a mean of 21 years. There were 100 primigravidae
(83%) of a mean age of 18.7 years. The eclamptic type was
29 ante partum (had eclampsia but not in labor on admis-
sion), 76 intra partum (labor pains predated the convul-
sion) and 16 post partum cases. Most (58) of the intra-
partum type of eclampsia came in advanced stage of labor
with no fetal heart activity and vaginal delivery was
achieved in those cases. There were 7 cases of craniotomy
for obstructed labor with fetal demise and 14 patients had
caesarean sections (11.5%) for cephalo-pelvic dispropor-
tion or fetal distress.
Repeat fits occurred in 9 patients (one ante partum, seven
intrapartum and one post partum). None of those that
had craniotomy had repeat fit. In 6 of the patients the fits
reoccurred within the first hour of loading dose while in
the remaining 3 the fits reoccurred within 4 hours of the
loading dose. This was the group that had the 12-hour
maintenance doses after aborting the repeat fit with an
additional 2 grams of magnesium sulphate.
There were 12 maternal deaths (7 from cardiopulmonary
failure, 4 from cerebro-vascular accident and one from
septicemia following caesarean delivery for obstructed
labor with live fetus). Only one of the maternal mortali-
ties was in the recurrent fit group and cerebro-vascular
accident was the probable cause of death. Case fatality rate
was 9.9%. There were 67 still births (58 of the fetal deaths
occurred before hospital admission).
Discussion
The incidence of eclampsia within the study period was
5.2% which is similar to figures obtained from some cent-
ers in Nigeria [3,4,16] and underscores the magnitude of
the disease even though it could be argued that the calcu-
lated rate was based on number of hospital deliveries
rather than being population-based. Other factors found
associated with eclampsia in this study were young mater-
nal age; primigravidity and lack of prenatal care which are
similar to what have been reported by other workers
[16,17].
The ultra short regimen of 14 grams loading dose of mag-
nesium sulphate was effective in 92% of cases in this
study. The concept of using just the loading dose of mag-
nesium sulphate to control and prevent fits in eclampsia
was suggested by Boyd and Brower [18] but the first com-
prehensive study was published in 2002 [19]. It was
shown in that study that the recurrent convulsion rate was
almost the same (3.96% versus 3.52%) between the group
that had only a loading dose of 10 grams (4 gram intrave-
nous and 6 gram intramuscular) and the control group
that had both the loading dose and the maintenance
doses of 2.5 grams four-hourly for 24 hours. However,
one of the limitations of the study was that it was not dou-
ble-blind with the possibility of allotment bias. The main
difference between our study and the loading dose arm of
that study was that we used 14 grams but they used 10
grams and we recorded a 7.4% recurrent fit as against their
3.9%.
Why would small doses or an ultra short regimen of mag-
nesium sulphate be effective in eclamptics? We do not
have an explanation but some workers have suggested a
small body mass index [19]. Unfortunately, it was very
difficult to weigh and calculate body mass index of most
of the patients in our study for they were either deeply
unconscious or in advanced stage of labor at the time of
admission. Even then a small body mass index alone
might not explain the whole phenomenon, for some
authors have shown that there was no association
between treatment failures and body mass or with serum
magnesium levels [20].
The ultra short regimen used in this study is attractive for
many reasons. In the first place, it minimizes the risk of
toxicity since most patients would not need the mainte-
nance doses. Clinical monitoring for magnesium sulphate
toxicity as prescribed by eliciting patellar reflexes, count-
ing respiratory rate and measuring urinary output could
be religiously undertaken at tertiary hospitals where there
are adequate manpower, facilities and supervision. But
manpower in particular is a challenge at the district hospi-
tals and primary health care centers of many developing
countries. We have also observed that in some patients
with eclampsia, the deep tendon reflexes could be
adjudged equivocal or absent even before the initiation of
magnesium sulphate therapy if there is a decision to
administer the drug; hence tendon reflexes cannot be
completely relied upon as an early sign of toxicity under
such a situation. Secondly, the cost of treatment using the
ultra short regimen is about a third of the standard regi-
men and this would be a welcome development in
resource poor countries. Perhaps of immense importance
is the observation from this study that majority of eclamp-
tic patients that would have a repeat fit will do so within
one hour of the loading dose and thereby giving the
health worker the opportunity to identify those that
would need the maintenance doses.
A case fatality rate of 9.9% even though high is still better
than the 29% recently reported from Nigeria [21]. Larger
trials have found that magnesium sulphate when used as
anticonvulsant for eclampsia is associated with low mater-
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The very poor perinatal outcome in this study is of serious
concern and very disturbing but there were as many as 58
fetal deaths at the time of admission of the patients. It is
sequel to late presentation to the health facility. Many rea-
sons have been advanced for eclamptic patients present-
ing late amongst which is the belief that eclampsia is
caused by 'iska' which translate literarily to mean 'spirit'
thus treatment from orthodox medicine is sought only
after other options have failed. Also it might take time to
get the necessary clearance and permission from the hus-
band for a woman to be allowed out of the house even at
times of emergency especially if the man is not at home.
This is the subject of an on-going research (Adamu AN;
personal communication).
Conclusion
In conclusion, the ultra-short protocol of 14 grams mag-
nesium sulphate given 4 grams intravenously and 10
grams intramuscularly was effective as an anticonvulsant
in 92.6% of eclampsia patients in the study area. Only 7%
of the patients needed the continuation of the mainte-
nance doses. However a properly conducted, multi-center,
randomized controlled trial is recommended to test this
proposed regimen.
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